Further, both the rate and incidence of hypoglycaemia with IGlar in this meta-analysis were consistent with that reported in other trials 26–28, including the Treat-to-Target trial, in which overall confirmed and nocturnal confirmed hypoglycaemic episodes were reported at the respective rates of 3.0 and 1.3 episodes per PYE in insulin-naïve subjects treated with IGlar, respectively 7. Here, INS is linked to Hypoglycemia.